Info

🌱來自：renal-cell-carcinoma

mTOR inhibitors-of-renal-cell-carcinoma

• 1° endpoint(s) listed below include PFS,
• OS at interim analysis Class S/E: Stomatitis,
• fatigue,
• rash,
• edema,
• pneumonitis,
• hyperglycemia,
• hyperlipidemia,
• ↓ WBC,
• ↓ PLT Everolimus (Lancet 2008;372:449) vs. placebo: PFS: 4 mos vs. 1.9 mos (HR: 0.30, P <0.0001) Temsirolimus (NEJM 2007;356:2271) vs. IFNα: OS: 10.9 mos vs. 7.3 mos (HR: 0.73, P = 0.008)

Siblings

• Epidemiology-of-renal-cell-carcinoma
• Histology and molecular biology-of-renal-cell-carcinoma
• Hereditary RCC and germline testing-of-renal-cell-carcinoma
• Clinical presentation-of-renal-cell-carcinoma
• Staging (TNM classification) and prognosis-of-renal-cell-carcinoma
• Treatment principles-of-renal-cell-carcinoma
• Systemic therapy for metastatic clear cell RCC
• Second-line therapies-of-renal-cell-carcinoma
• Combined-modality therapies-of-renal-cell-carcinoma
• Tyrosine kinase inhibitors-of-renal-cell-carcinoma
• Immunotherapies-of-renal-cell-carcinoma
• mTOR inhibitors-of-renal-cell-carcinoma
• Non-clear cell histology-of-renal-cell-carcinoma